Effectiveness of a Short Term Induction Regimen of a Biosimilar Adalimumab in the

Long Term Management of Symptomatic Ankylosing Spondylitis: A Community

Based Proof of Concept Observational Study

*Chopra Arvind, Khadke N, Saluja M, Kianifard T, Venugopalan A

Authors Affiliation: Department of Rheumatology, Centre for Rheumatic Diseases,

Pune, India

Address for Communication:

Dr Arvind Chopra

Centre for Rheumatic Diseases.

Hermes Elegance, 1988 Convent St., Camp

Pune, 411001 India

Correspondence to : <u>arvindchopra60@hotmail.com</u>; <u>crdp5624@gmail.com</u>

*ORCID:0000-0002-4347-9651

Drug Trial Registration: Clinical Trial Registry of India vide reference

CTRI/2018/02/012018 dated 20 Feb 2018 (retrospectively registered) and available at

http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=19498&EncHid=&userName=adal

imumab.

ABSTRACT

Introduction: Cost and drug toxicity often deter prolonged therapeutic use of anti-TNF

agents in ankylosing spondylitis (AS). A planned study was completed to endorse our

clinic based observation of long term relief following short-term administration of

anti-TNF agent.

Methods: 50 consenting patients with symptomatic active chronic AS under

rheumatology care in a community clinic were enrolled. They had no past history of

anti-TNF use. 40 mg standard biosimilar adalimumab (BS-ADA, Exemptia trade

name)was injected subcutaneously every fortnight for six injections (10 weeks).

Patients were monitored at several time points. Improvement was assessed at regular

interval as per protocol which included standard indices (Bath and Assessment

Spondyloarthritis International Society /ASAS). An intention to treat analysis with

significant p<0.05 was carried out.

Results: Patients showed early and substantial significant improvement in pain, NSAID

requirement, function and in several indices (ASAS 20 & 40, ASAS partial remission,

BASDAI, BASFI, ASDAS) which persisted after stopping injections. 84% and 52 %

of patients respectively showed ASAS 20 improvement at week 12 and 48:

corresponding ASAS partial remission 34% and 24%. Over 50% patients maintained

prolonged improvement and provided proof of concept (defined a-priori). Serum

Interleukin-6 assay showed a sharp reduction at 24 weeks. None developed TB or

serious drug toxicity. 11 patients withdrew (mostly inadequate response). Absence of

control was a limitation.

Conclusion: A ten-week administration of biosimilar adalimumab in difficult to treat AS

showed early substantial improvement which often persisted for 24 weeks. This

unconventional strategy was socioeconomically appealing. It merits further validation and acceptance especially in resource strained settings.

Key Words: ankylosing spondylitis, treatment, Adalimumab, biosimilar, clinical practise

INTRODUCTION:

of axial skeleton and sacro-iliac joints and causes substantial limitation in spine motion, spine deformity, systemic complications and premature mortality [1]. The newer imaging modalities offer early diagnosis and assessment of skeletal damage [2]. AS is a life long and difficult to treat disorder [3]. NSAID (non-steroidal anti-inflammatory

Ankylosing spondylitis (AS) is a prototypic autoimmune inflammatory painful disorder

drugs) remain the mainstay of symptomatic treatment. The benefit of conventional

DMARD (Disease modifying anti rheumatic drugs) is debateable, whereas anti-tumour

necrosis factor (TNF) drugs and other biologic DMARD are more effective and

recommended for long term use[3]

The prevalence of AS in India was reported to be 0.03% (95% confidence interval 0.02,

0.05) but this would mean a substantial disease burden [4]. The unaffordability and risk

of infections including tuberculosis (TB) remain a deterrent for widespread use of

biologic DMARDs in India.

Several biosimilar anti-TNF drugs were launched globally to improve the access and

affordability (5, 6). Adalimumab (HumiraTM) is a popular anti-TNF drug but not

marketed in India. In 2014, a standard biosimilar Adalimumab (Exemptia[™], Bs-ADA)

was marketed in India [7,8] A generous donation of ExemptiaTM was instrumental in

facilitating the current non-commercial investigator initiated study.

A repeatedly observed prolonged symptomatic relief following a shorter period (non-

standard) of treatment with Infliximab or Etanercept in several patients of AS in clinical

practise inspired the author (AC) to experiment with a new concept. A preliminary

report was presented in the 2005 APLAR Congress [9]. Short term therapy seemed

effective and safe, and certainly more acceptable to the patients. The current study was

planned with this perspective in mind.

The aim of the study was to evaluate the prolonged effectiveness and safety of a short

term regimen (6 injections) of a biosimilar Adalimumab in the treatment of active

chronic symptomatic AS.

PATIENTS AND METHODS:

This was a prospective interventional uncontrolled single centre study of one year

duration. The design was observational and it was carried out in a popular community

rheumatology clinic (Centre for Rheumatic Diseases, Pune, India) from June 2016 to

July 2018. The protocol adhered to the guidelines of the updated Declaration of

Helsinki and was approved by the local ethics (CRD, Pune) committee and registered

(CTRI/2018/02/012018) [10].

Inclusion criteria included (i) clinical diagnosis of AS made by a rheumatologist (ii)

Patients aged between 18 to 75 years (iii) symptomatic disease and fulfilling any two of

the following three criteria anytime during the previous week (a)muscular-skeletal axial

pain VAS of 3 cm or more (range 0 to 10 cm) for over three months (b) early morning

stiffness of 30 min or more (c) Erythrocyte Sedimentation Rate (ESR, Westergren

method) ≥ 28 mm end first hour or C-Reactive protein assay (CRP) ≥ 6 mg/l and (iv)

bony erosions and or ankylosis as evident from a plain digital standard skiagram of the

pelvis for sacro-iliac joints (v) patients requiring frequent NSAIDs who have been on a

stable dose for at least 4 weeks (vi) duration of disease ≥ 2 years.

Exclusion criteria included (i) arthritis and/or axial spine pains due to any other cause

except reactive arthritis (ii) biological agent use (especially anti-TNF) during the

previous two years (iii) DMARD use except sulphasalazine and or methotrexate during

the previous 12 weeks (iv) steroid use in the previous 4 weeks (v) recent onset of a

potentially serious medical disorder (such as diabetes or cardiovascular disease) (vi)

history of any recent infection requiring antibiotics in the last 12 weeks (vii) history of

past tuberculosis irrespective of the nature of treatment provided (viii) past history of

hepatitis or human immunodeficiency virus (HIV) (ix) history of cancer or

lymphoproliferative disease (x) exposure to any kind of hazard or risk by virtue of

participation in the study as judged by the investigator

Selection, Screening and Enrolment: Potential patients were identified from the

outpatient clinic (CRD, Pune) where a comprehensive clinical database exists since

1998. After signing the informed consent form patients were examined for eligibility

and enrolled on first-come-first-serve basis.

Study Visits: After enrolment, patients visited the study site (CRD) every two weeks

during the initial 10 weeks to receive the Bs-ADA injection (total 6 injections) and

subsequently at 12, 24, 36 and 48 week (one year study completion) endpoint.

Study and Concomitant Medication: 40 mg Bs-ADA (Biosimilar Adalimumab) was

injected subcutaneously every fortnight as per protocol. Patients who failed to achieve

ASAS 20 index response at week 12 were randomized to receive two more fortnightly

injections (Bs-ADA) or continue routine follow up. BS-ADA was not repeated ever

thereafter.

Patients were counselled on pain relief and use of NSAID (AC, NK). They were

prescribed a daily therapeutic dose of NSAID for the initial 4 weeks and thereafter

switched to need-for basis (prn) as judged by the rheumatologist (Table 1). Patients

were encouraged to record daily NSAID use in a personal diary. Patients were allowed

oral paracetamol (one 650 mg tablet 1-2 times daily) and or tramadol (50 mg tablet, 1-2

times daily) for intolerable pain. Patients were monitored every two weeks for the initial

twelve week period.

Most of the patients used Etoricoxib (60 mg and 90 mg tablets, India Pharmacopeia)

prior to enrolment and were permitted to continue the same (initially 60-120 mg daily)

after enrolment (Table 1). The use of other NSAID was permitted but the dose was

converted into Etoricoxib equivalent for the purpose of compiling the mean daily

NSAID dose data (Table 1). One thousand milligram Naproxen or 150 mg Diclofenac

or 100 mg Indomethacin or 900 mg Etodolac was considered equivalent to 120 mg

Etoricoxib as decided a-priori by author (AC).

Steroids in any form were not permitted. Patients continued medicines for any other

coexistent disease with primary care physician.

Efficacy Measures: A routine standard rheumatology case record form and other

standard AS questionnaires, including those recommended by ASAS (Assessment

Spondyloarthritis International Society) were employed [2,11-14]. Patients also

completed the Indian version of HAQ (modified Stanford Health Assessment

Questionnaire) [15].

Important measures were as follows: (i) VAS (visual analogue scale) was used to record

musculoskeletal pain (maximum pain experienced in the previous 24 hours), patient and

physician global assessment (current) and general health (current). It was a horizontal

line anchored at 0 for nil and 10 for optimum value (ii) NSR (numeric scale rating) with

10 marked categories (1-10) on a horizontal scale (iii) BASDAI (Bath disease activity

index): 6 questions marked on NSR to evaluate symptoms pertaining to previous week -

fatigue, neck-back-hip pains, pain/swelling in peripheral joints, discomfort on eliciting

local tenderness (entheses), duration and severity of early morning stiffness (iv) BASFI

(Bath functional index):10 items marked on NSR for daily bodily activities such as

climbing steps, doing work related tasks etc (v) ASAS 20 index improvement response

was the primary efficacy variable and evaluated 4 domains- patient global assess,

overall pain, function (BASFI) and inflammation (mean of BASDAI questions 5 & 6

pertaining to morning stiffness); achieved with a minimal 20% improvement with at

least 1 unit improvement in NSR in 3 of the 4 domains without any worsening in the

remaining domain (20% or more and more than 1 unit) (vi) ASAS 40 index

improvement response: domains similar to ASAS 20 but requiring 40% improvement

and minimal 2 unit improvement in NSR and without any worsening (vii) ASAS partial

remission required none of the 4 domains in ASAS 20 to exceed 2 on the NSR (viii)

ASAS 5/6 response required at least 20% improvement in 5 of the 6 domains (ASAS 20

domains plus domains of lateral spine flexion and CRP assay) (ix) ASDAS (disease

activity score), a weighted index, was computed using a standard online program and

included total back pain, patient global disease activity, peripheral painful/swollen joint,

morning stiffness and ESR.

Patients were required to report to the study site in a fasting state (without intake of

meal or any study drug) during the morning hours (8-11 am) of the scheduled visit.

Safety Evaluation: Adverse events (AE) were recorded in the CRF

Laboratory Evaluation: Patients completed laboratory investigations during screening

and at baseline and at week 4, 8, 12, 24, 36 and 48 (one year) endpoints as per protocol.

These included routine hemogram, blood sugar, metabolic hepatic and renal profile,

urine analysis, Erythrocyte Sedimentation Rate (ESR, Westergren method, normal

range: for men-less than 20 mm and for women-less than 30 fall end of 1st hour) and C

- reactive protein titter (CRP, Nephelometry, normal range 0- 5 mg/dl). Patients were

screened for latent TB using standard skin tuberculin testing (5 TU intradermal), blood

TB (gamma interferon release assay and skiagram of chest [16]. Commercially available

ELISA kit was used to assay selected cytokines- TNF alpha, Interleukin (IL)-6 and IL-

17.

Patient Expenditure: The Biosimilar Adalimumab (ExemptiaTM) was provided free of

cost to 13 patients and at almost 50% concessional market rate to the rest of the

participants in the study. Patients purchased their own NSAID and analgesic. All

investigations were carried out free of cost. Patients were given a modest monetary

allowance for travel and meals.

Statistical design and data analysis: A convenient (non-probabilistic) sample size was

chosen by AC (lead author) based on local resources but with an emphasis on at least 35

participants. A 20% drop out rate was anticipated by AC based on earlier experience.

Appropriate statistical test were performed using a standard statistical package (SPSS

version 2007, USA) with significance at p< 0.05, two sided. Quantitative variables were

analysed for mean, median, Standard deviation (SD), proportions and 95% Confidence

Interval (CI). An intention to treat analysis (last observation carried forward) was

completed. ASAS 20 was the primary efficacy response at week 12, 24, 36 and 48

9

endpoints

The proof of the concept (see above) in the current study was to be accepted if at least

50% of the patients with ASAS 20 response at week 12 (two weeks after cessation of

treatment with Bs-ADA) showed persistence of response for another 24 weeks (at week

24 and week 36 endpoints).

A conventional survival analysis (life table method) was also carried out with the

'survival' defined as an absence of the event (such as ASAS 20, ASAS 40, ASAS 5/6

response, ASAS partial response) that persisted for at least eight weeks.

OBSERVATION AND RESULTS:

Fig 1 shows the disposition of patients in the study. 60 patients were screened and 50

patients (42 men) were found eligible and enrolled. In retrospect, all patients satisfied

the standard classification criteria for AS [2,17].

The mean age and duration of illness were 31.2 (SD ±9, Range 19-56) years and 99.5

(SD± 67.8, Range 13-312) months, respectively. 86% patients tested positive for HLA

B27. All patients had consumed multiple courses of more than two NSAID, often

supervised, during the recent past period as per medical records. The NSAID use and

consumption is shown in Table 1. 28 patients provided a past history of a supervised

prolonged (at least six months) intake of standard DMARD (sulphasalazine and/or

methotrexate).

Patients showed a moderately severe symptomatic active disease as shown by pain VAS

and other individual variables (Table 2). The baseline mean spine pain, based on

BASDAI questionnaire, was 6.8 ± 2.1 (SD) (range 0-10 cm). 42 patients (84%) were

10

classified with a 'very high disease activity' state as per ASDAS [14].

Withdrawals: 11 patients withdrew and mostly because of poor therapeutic response.

None of the withdrawals were due to an AE (Fig 1). 1 patient developed intolerable hip

pain and underwent hip arthroplasty after 30 weeks of study.

NSAID: Table 1 shows the quantitative use of NSAID (Etoricoxib). 9 patients used

other NSAID (3 Indomethacin, 3 Naproxen, 2 Diclofenac sodium, 1 Etodolac) and their

dose was converted to Etoricoxib equivalent (see method). The mean pain VAS after

two weeks was 4.2±2 (SD). However, a substantial reduction in the use of NSAID was

observed after patients completed 4 weeks of study (3 Bs-ADA injections). Less than

15% patients required daily NSAID after 8 weeks. 4 of the nine patients who consumed

NSAID daily at week 12 showed ASAS 20 index response.

Effectiveness (Table 2, Table 3): The ASAS 20 improvement at week 12 was seen in 41

(82%) patients (95% CI 69.2%, 90%) and ASAS 40 in 35 (70%) patients (95% CI 56.2

%, 80.9%). Over 50% patients achieved ASAS 20 response at all primary efficacy time

points (Table 3). 21 patients (42%) showed persistence of ASAS 20 index improvement

at week 12, 24 and 36 time points and provided proof of the concept (see statistical

design and data analysis).

Patients improved significantly with early response which persisted, albeit with some

decline, till the study completion at 48 weeks (one year) (Table 2, Table 3, Fig 2) The

optimum improvement was shown at week 12. Based on ASDAS, inactive/low disease

activity was classified in 28 patients (56%) at week 12, 18 patients (36%) at week 24,

12 patients (24 %) at week 36 and 10 patients (20 %) at week 48 endpoint;

corresponding 'major improvement' seen in 64%, 50%, 36% and 28% patients [14].

Survival Analysis (Online Resource 1 and Online Resource 2): ASAS 20 achieved a

high cumulative proportion ($\neg 80\%$) in the cohort within 4-12 weeks of study. ASAS 40

and ASAS 5/6 showed a similar pattern (time to event) but the cumulative proportion

was less $(\neg 50\%)$ and the curve remained near flat (minimal increment) thereafter. The

time to event for optimum (¬30%) cumulative proportion for ASAS partial remission

event was seen later at 12-24 week interval and it remained near flat thereafter (week

36: 95% CI 20%, 45%).

Non-respondents: 7 patients who were examined at week 12 failed to achieve ASAS 20

response. Despite 3 randomized patients receiving additional two Bs-ADA injections (

see methods), none of the non-respondents achieved an ASAS 20 response thereafter.

Safety and tolerability: None of the patients suffered from serious AE. There were no

deaths. None developed symptomatic TB. 10 patients reported mild AE which resolved

with standard care and none showed local site reaction (3 patients nasopharyngitis, 3

patients dermatophytosis, 2 patients non-specific body aches and pains, 2 patients mild

uveitis, 1 patient nasal polyp bleed, 1 patient itchy eczema over ankle region).

Cytokine Assay (Figure 3): Pro-inflammatory cytokines assay (IL-6, TNF α and IL-17)

showed a reduction at week 24 and week 48 as compared to baseline and was

substantial for IL-6 assay at week 24 (p<0.05).

DISCUSSION:

This prospective observational study of one year duration demonstrated an early onset

of significant and substantial improvement in patients suffering from active chronic

symptomatic AS after treatment with a biosimilar Adalimumab administered over 10

weeks (six injections). The patients had shown an inadequate response to NSAID prior

to enrolment and the consumption (NSAID) was reduced considerably and persisted over prolonged period (Table 1). Significant and considerable improvement persisted for several variables and indices (Table 2 and Table 3), albeit with a modest decline after stopping Adalimumab. Eighty two percent patients showed ASAS 20 index improvement (primary efficacy) at week 12 and the response persisted in over 50% patients for at least 24 weeks (proof of the a-priori study concept). 11 patients withdrew because of inadequate improvement. All AE were mild. The study was carried out in a real-life community practise setting.

The extent of improvement desired by a patient suffering from chronic AS is difficult to assess. Several standard index responses (ASAS, BASDAI, BASFI, and ASDAS) were used in the current study to show a multifaceted improvement [2]. These indices also demonstrated persistence of good improvement during the study period as shown by the survival curves (Supplementary Fig 1). There was comparatively less improvement with ASDAS. (Table 3). In our experience, patients often struggle to quantify morning stiffness and we believe that some of the study patients failed to donate blood samples in a fasting state because of difficult personal logistics.

Interestingly, the ASAS partial remission in the current study was 34% at week 12 (Table 3) and more or less persisted after stopping Adalimumab (Supplementary Table 1 and Fig 1). It is difficult to define remission in chronic AS [18]. Up to a third of patients treated with NSAID and up to two-thirds treated with anti-TNF agents are reported to achieve ASAS partial remission with higher response seen in patients with more recent disease [18]. Spontaneous remission in AS is rare and partial remission (ASAS) was reported in 1.03-5.6% patients on placebo in anti-TNF studies [18].

Current recommendations advocate long term use of anti-TNF agents in AS. Several patients relapsed within 6 months of stopping infliximab after using it regularly for three years [19]. But in the current study several patients continued to enjoy symptomatic improvement (Table 2, Table 3, Fig 2) with good function (low BASFI) for at least 24 weeks after receiving 6 injections of Bs-ADA. Perhaps short term therapy (anti-TNF) can be used further in a cyclical manner (10 week therapy every 24 weeks) in some patients with difficult AS resulting in good efficacy and safety. But this needs to be validated in suitable long term clinical studies.

There were several other limitations and strengths. The study was uncontrolled and carried out in a single centre with a small sample size. The basic concept in the study was inspired by a therapeutic need and the clinical observations of the author (AC) [5]. However, the protocol was pragmatic in nature and patients were managed in a community setting and showed good compliance; 6 of the 11 withdrawals were after 36 weeks of study (Fig 1). Several of the current selection criteria and methods were influenced by the experience of the author (AC) and differed from standard recommendations (ASAS) and regulatory drug trial studies [3,20]. The placebo effect arising from the patients expectations regarding Bs-ADA must have influenced the overall outcome especially in the initial phase. The current study did not assess anti-ADA antibodies and radiological (structural) changes and the benefit of long term use of anti-TNF agents on the bony lesions in AS seems to be modest [21]. The current study adhered to the requirements of longitudinal observational drug studies in rheumatology as advocated by EULAR (22).

Prolonged use of NSAID in AS is a standard of care and a good symptomatic response is expected within 2 weeks [3]. A randomized controlled study of a daily fixed dose of

Etoricoxib over one year duration demonstrated excellent efficacy and safety in patients with AS although the disease duration was not described and both 90 mg and 120 mg groups showed almost a similar outcome [23]. Prior to enrolment, 77.4% patients flared considerably following the wash out phase. The reduction in pain after two weeks was substantial and persisted till study completion (one year). At week 6, the ASAS 20 index improvement was 64.8% and the ASAS partial remission was about 15%. In another randomized controlled study of 24-week duration, a combination of infliximab and naproxen was significantly superior to naproxen alone and both groups showed significant early pain relief by two weeks and a persistent reduction in BASDAI and CRP; the disease duration was less than 3 years [24].

In the current cohort, patients suffered from active chronic AS and the response to NSAIDs had been inadequate. Etoricoxib is the preferred NSAID in our clinic for AS treatment.. Despite previous regular daily use, the baseline (week 0) pain was moderately severe (Table 2). However, patients continued Etoricoxib with the therapeutic dose along with Bs-ADA. The reduction in pain after 4 weeks (-2.2. 95% CI -2.77,-1.65) was considerable and significant (Table 2) and a substantial and persistent reduction in the requirement of NSAID was observed (Table 1). Patients stopped Bs-ADA after week 10. Less than 15 patients admittedly consumed oral paracetamol and/or tramadol infrequently on a need-for basis during the initial 12 weeks (data not shown). Though the selection criteria and study design differed considerably, the extent of active painful disease in the two NSAID drug trials described above were comparable to the current study.

There was no wash out period in the current study. The pain relief to NSAID (Etoricoxib) in the current study was relatively less. It is difficult to vouch for the data

on NSAID use shown in Table 1 though we are largely certain. It was largely based on patient compliance and recall which can be difficult to judge. The data pertaining to the daily use of NSAIDs and absent use is likely to more reliable (Table 1). Etoricoxib may not be the best NSAID for all patients. We often encounter patients (and community) who express intense fear of consuming NSAIDs and analgesics because of the potential life-threatening side effects and so our expert counselling often fails. Yet there is still, a large majority of deserving patients of AS who cannot afford biologic agents although they would wish to make use of them. The results of the current study also ought to be considered against this community perspective.

In a randomized active controlled drug trial study, the ASAS 20 index response at week 24 was 75% patients in the Biosimilar Adalimumab (IBI1303) group and 72% patients in the innovator Adalimumab (HumiraTM) group [25]. The ASAS 20 index response at week 24 in the current uncontrolled study (intention to treat) was 68% but patients did not receive Bs-ADA beyond 10 weeks in the current study.

A recent AS registry study from India reported significant improvement in pain VAS and BASDAI after 24 weeks use of Bs-ADA (ExemptiaTM). However, only one third of patients had sufficient data for analysis [26]. None of the patients recorded in the Indian registry reported TB. A total of 124 patients suffering from ulcerative colitis and Crohn's disease received prolonged treatment with Bs-ADA (ExemptiaTM) in three Indian studies and nine developed TB [27, 28]. In the current study 6 patients tested positive for latent TB during the screening process and were excluded (Fig 1). A vigorous use of TB screening seems to have reduced the incident rate of TB in the drug trials of Adalimumab in rheumatic disorders from 1·5 to 0·2 per 100 patient years [29].

Compared to baseline, the serum TNF α assay showed a progressive reduction, albeit

modest, at week 24 and 48; correspondingly IL-17 assay showed a modest rise and then

fall (Fig 3). In contrast, IL-6 showed a significant reduction at week 24 (consistent with

the CRP assay in Table 2); the assay was much higher at week 48 and probably

reflected a rise in CRP along with conspicuous decline in the clinical improvement.

Serum assay of pro-inflammatory cytokines was reported in patients of

spondyloarthritis treated with anti-TNF agents but is not standard care [30].

Finally, the author (AC) has managed several more patients of AS in clinical practice

(CRD) employing short term use (12-16 weeks) of anti-TNF agents, both innovator and

biosimilar and have shown clinical improvement similar to the current report without

encountering single case of TB (unpublished). Patients in dire need for anti-TNF agent

but with a positive test for latent tuberculosis are invariably treated with a six month

standard course of INH prophylaxis.

In conclusion, the current study has demonstrated a remarkable degree of clinical

improvement with a 10 week standard regimen (six injections) of Bs-ADA

(ExemptiaTM) in patients suffering from symptomatic active chronic AS with an

inadequate response to NSAID. The clinical response persisted for at least 24 weeks in

several patients after discontinuation of the Bs-ADA. The regimen was well tolerated

and safe. Short term use of Bs-ADA seems a viable option to treat difficult AS in

resource strained setting such as ours. However, further validation will be required

17

before it can be accepted as a standard treatment modality for AS.

Authors contributions:

Conceptualization: Arvind Chopra; Methodology: Arvind Chopra, Manjit Saluja,

Nagnath Khadke, Toktam Kianifard, Anuradha Venugopalan; Formal analysis and

investigation: Arvind Chopra, Anuradha Venugopalan; Writing - original draft

preparation: Arvind Chopra; Writing - review and editing: Manjit Saluja, Anuradha

Venugopalan; Funding acquisition: Arvind Chopra; Resources: Arvind Chopra,

Anuradha Venugopalan, Manjit Saluja; Supervisor: Arvind Chopra, Manjit Saluja

Acknowledgment:

Arthritis Research Care Foundation-Centre for Rheumatic Diseases CRD), Pune, India,

provided generous material and logistic help for the study, and all patients were

investigated free of cost as per the protocol. Zydus Cadilla India provided substantial

concession to several needy patients in the current study to purchase the Biosimilar

Adalimumab (study drug). Several colleagues (rheumatologist) assisted in the study

and namely Dr Abraham Mohan, Dr Kiran Adams and Dr Amit Jain. Mr Sushil

Chaudhari provided immense help in administration and data entry. Dr S Sarmukaddam,

senior biostatistician, provided expert assistance for the statistical plan and analysis. We

remain indebted to our patients who wholeheartedly participated in the study and

continue in the ongoing long term follow up.

Disclosures:

All the authors of the current study are full time employees of CRD Pune and did not

receive any personal payment or compensation from any source towards the current

18

study or current publication.

Conflicts of interest/Competing Interest:

It is confirmed by Arvind Chopra (first author) that neither he nor any of the current

authors has any conflict of interest.

Funding:

Zydus Cadila India donated a substantial quantity of biosimilar Adalimumab

(ExemptiaTM) injections for free use by the deserving and needy patient participants in

the study and further provided an unrestricted educational and research grant to Arthritis

Research Care Foundation-Centre for Rheumatic Diseases CRD), Pune, India.

Availability of data and material:

All study related medical and other records are archived in Centre for Rheumatic

Diseases (CRD), Pune, India. An e-database was created to capture the data required for

study analysis and access will be provided one year after publication after a formal

request inclusive of purpose of data access to the first author (Dr Arvind Chopra) of the

current study.

Ethics approval:

Approval was obtained from the ethics committee of Centre for Rheumatic Diseases,

Pune, India, and the procedures used in this study adhere to the tenets of the Declaration

of Helsinki.

Consent to participate:

Informed consent was obtained from all individual participants included in the study.

Consent for publication:

No specific data or photograph of any kind of a study participant is used in this study.

Data Transparency:

All data and materials as well as software application or custom code used in the current study support the data presented and claims made in the current study and comply with the field standards of scientific writing, credibility, authenticity and personal honesty.

REFERENCES

- 1. Braun J, Sieper J (2007) Ankylosing spondylitis. Lancet 369(9570):1379-1390.
- Sieper J, Rudwaleit M, Baraliakos X, et al (2009) The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 68 (Suppl 2):1-44.
- Ward MM, Deodhar A, Akl EA et al (2016) American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 68(2):282-298.
- Chopra A (2015) Disease burden of rheumatic diseases in India: COPCORD perspective. Indian J Rheumatol 10(2):70-77.
- 5. Chopra A, Shankar S (2012) Biosimilar DMARD in rheumatology: A general perspective with focus on India. Indian J Rheumatol 7(2): 89–96.
- 6. Kay J, Smolen JS (2013) Biosimilars to treat inflammatory arthritis: the challenge of proving identity. Ann Rheum Dis 72(10):1589-93

- 7. Bandyopadhyay S, Mahajan M, Mehta T, et al (2015) Physicochemical and functional characterization of a biosimilar adalimumab ZRC-3197. Biosimilars 5:1-18.
- 8. ExemptiaTM (Adalimumab). Available from https://exemptia.com/adalimumab-india.html. Accessed on 14 Sept 2020.
- Chopra A, Lagoo-Joshi V, Kunjeer V 2005. Our experience with anti-TNF therapy - A choice between the devil and the deep sea. APLAR J Rheumatol 9: A208.
- 10. http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=19498&EncHid=&userNa
 me=adalimumab. Accessed on 26 Mar 2021
- 11. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286-2291.
- 12. Calin A, Garrett S, Whitelock H, et al (1994). A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21(12):2281-2285.
- 13. Lukas C, Landewe R, Sieper J, et al (2009). Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 68(1):18-24.
- 14. Machado P, Landewé R, Lie E, et al (2011) Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 70:47–53.
- 15. Chopra A, Saluja M (2012) Validation and usefulness of Indian version (CRD Pune) health assessment questionnaire: Drug trials, community practice and

- COPCORD Bhigwan population study (1994–2012). Indian J Rheumatol 7(2):74–82.
- 16. Chandrasekaran P, Mave V, Thiruvengadam K, et al (2018) Tuberculin skin test and QuantiFERON-Gold In Tube assay for diagnosis of latent TB infection among household contacts of pulmonary TB patients in high TB burden setting. PLoS One 13(8):e0199360.
- 17. Dougados M, van der Linden S, Juhlin R, et al (1991) The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34(10):1218-1227.
- Poddubnyy D, Gensler LS (2014) Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis. Best Pract Res Clin Rheumatol 28(5): 807–818. doi:10.1016/j.berh.2014.10.005.
- 19. Baraliakas X, Listing J, Brandt J, et al (2005) Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after three years of continuous treatment with infliximab. Arthritis Res Ther 7: R439-444.
- 20. van der Heijde D, Kivitz A, Schiff MH, et al (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicentre, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54(7):2136-2146.
- 21. Louie GH, Ward MM (2014) Measurement and treatment of radiographic progression in ankylosing spondylitis: lessons learned from observational studies and clinical trials. Curr Opin Rheumatol 26(2):145-150.

- 22. Zavada J, Dixon WG, Askling J (2013). Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis, 73(3):628.
- 23. van der Heijde D, Baraf HSB, Ramos-Remus C et al (2005) Evaluation of the Efficacy of Etoricoxib in Ankylosing Spondylitis. Arthriris Rheum 52 (4): 1205–1215.DOI 10.1002/art.20985.
- 24. Sieper J, Lenaerts J, Wollenhaupt J et al (2014) Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis 73: 101-107.
- 25. Xu H, Li Z, Wu J, et al (2019) IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trial. The Lancet Rheumatology 1(9):E35-E43. Available from: https://doi.org/10.1016/S2665-9913(19)30013-X. Accessed on 10 June 2020.
- 26. Kapoor S, Kaushik VV, Jain R, Rao VKR, Gharia M (2019) Real-life Tolerability and Effectiveness of Adalimumab Biosimilar in Ankylosing Spondylitis: the Adalimumab Biosimilar Patient Registry Data. ACR Open Rheumatol 1(8):480-484.
- 27. Midha V, Mahajan R, Mehta V, et al (2018) Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate to severe ulcerative colitis. Intestine Res 16(1):83–89.

- 28. Chandra A, Kanth R, Thareja S (2019) Efficacy and Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up. Biologics: Targets and Therapy 13(11):191–200.
- 29. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP (2013). Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 72(4):517-524.
- 30. Keller C, Webb A, Davis J (2003) Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review. Ann Rheum Dis 62(12):1128–1132.

TABLES:

Table 1: NSAID (Etorocoxib or Etoricoxib equivalent) consumption during the trial study of biosimilar Adalimumab (Bs-ADA) in patients (n=50) suffering from symptomatic moderately severe chronic Ankylosing Spondylitis: A single arm prospective observational study

Weeks, 0	0 to -	0 to 2	2 -4	4-6	6-8	8 -12	12-24	24-36	36-48	48+
Baseline	4*									
/ Variables										
Number	50	50	50	49	49	49	49	47	44	39
patients										
Mean daily	92.4	104.7	108.7	77.3	35.1	19.6	17.2	22.2	26.6	50.5
dose mg (SD)	(27.62)	(25.3)	(31)	(46.7)	(42.4)	(35.7)	(32,2)	(38.9)	(42.8)	(50.1)
**Continuous	50	50	45	37	17	9	4	6	9	17
use										
***On need	0	0	5	7	13	15	14	15	19	11
basis										
^Nil use	0	0	0	5	19	25	31	26	16	11

Note: Bs-ADA was injected using standard regimen for 12 weeks beginning at O Baseline; NSAID: non-steroidal anti-inflammatory drug; Mean daily dose pertains to Etorocoxib (NucoxiaTM/ EzycoxibTM & available as 60 mg and 90 mg tablet, India pharmacopeia); Over 90% patients consumed Etorocoxib in the study; Dose of any other NSAID converted empirically to Etorocoxib equivalent;*: minus prefix indicates period prior to baseline; 48+; study completion and a 12 week follow up; **: either od or bid, 60-120 mg Etoricoxib;***: 60 mg Etorocoxib od on need basis; ^:Advised need basis but did not require any NSAID use; See text for details especially for Etoricoxib equivalent

Table 2: Efficacy variables (Mean \pm Standard Deviation) at baseline and predetermined study time points in a study of biosimilar Adalimumab (administered for initial 12 weeks) in Symptomatic Ankylosing Spondylitis (n= 50 patients)- a single arm prospective observation study (95% confidence interval shown in parenthesis)

Variable/ Time	Baseline	Week 4 *	Week 8*	Week12 *	Week 24	Week 36	Week 48 *
points							
Pain VAS	5.9±2.0	3.7±1.7	3.2 ±1.9	2.6±2.1	3±2.4	3.6±2.4	3.92.2
	(5.3, 6.5)	(3.3, 4.2)	(2.6,3.7)	(2,3.2)	(2.3.3.7)	(2.9,4.2)	(3.3,4.6)
PATG	6.2±1.6	4 ±1.5	3.3±1.6	2.9±1.9(2.3,	32(2.6,	3.5±2.1	3.72.3
	(5.7, 6.6)	(3.6, 4.5)	(2.9,3.8)	3.4)	3.5)	(2.8, 3.9)	(3.1,4.4)
HAQ	5.3±3.7	3.1±2.8	2.5±2.4	2.1±2.8	3	3.5±3.2	3.4.4
	(4.2, 6.3)	(2.3, 3.9)	(1.8,3.1)	(1.4,3)	(2.2,3.9)	(2.6,4.4)	(2.5,4.4
ESR	88±30	29.1±20	31.4±20	33.929.1	54±33.2	69.837.2	68.5±33.2
	(80, 97)	(23.4,	(23.4,34.8)	(25.6,42.1	(43.4,62.3)	(59.3,80.5)	(59,78
		34.8)					
CRP	63.8 ±	9.6 ± 16.8	13.2 ±	10.9 ± 21.4	25.0 ±39.4	35.0 ±44.8	35.6 ± 38.0
	55.2	(4.8, 14.4)	29.6	(4.8, 17.0)	(13.8,	(22.3,	(24.8,
	(48.1,		(4.8, 21.6)		36.2)	47.8)	46.4)
	79.5)						

Note: See text for methods; All numerical values rounded to 1 decimal place; n: number; *: significant difference from baseline at p< 0.05 (ANOVA), intention-to-treat analysis; VAS: visual analogue scale; BASDAI: Bath disease activity index; ASDAS: Ankylosing Spondylitis disease activity score; PATG: patient global assessment; HAQ: Health assessment questionnaire (Indian version); ESR: Erythrocyte sedimentation rate (Westergren, mm fall end 1st hour); CRP: C-reactive protein (mg/l); Hb: haemoglobin (mg/dl)

Table 3: Proportion percentage (95% confidence intervals) of patients showing ASAS 20 (Primary efficacy response), ASAS 40, ASAS 5/6 and ASAS partial remission and mean of ASDAS (ESR), BASDAI and BASFI indices at predetermined study time points in a study of biosimilar Adalimumab (administered during the initial 12 weeks of study) in Ankylosing Spondylitis (n= 50 patients)- a single arm prospective observational study (95% Confidence interval shown in parenthesis, intention to treat analysis)

Study	ASAS	ASAS 40	ASAS-	ASAS 20	ASDAS	BASDAI	BASFI
visits	20		5/6	partial			
(weeks)				remission			
				Tellission			
0 Baseline	-	_	-	-	4.6(4.4,	5.3(4.7,	4.7(4,
					4.9)	5.8)	5.3)
4	56 42.3,	28 (17.5,	38(25.9,	4(1.1,	2.6	3(2.5,	3.1(2.5,
	68.8)	41.7)	51.8)	13.5)	(2.4,	3.5)	3.8)
					2.9)		
	74/60 4	50/44.2	54/50.1	16/0.2	2.4/2.1	2 2 / 1 0	2.4/1.0
8	74(60.4,	58(44.2,	64(50.1,	16(8.3,	2.4(2.1,	2.3(1.9,	2.4(1.8,
	84.1)	70.6)	75.9)	28.5)	2.7)	2.7)	3)
12	82(69.2,	70(56.2,	68(54.2,	34(22.4,	2.4(2.1,	1.8(1.3,	2(1.4,
	90.2)	80.9)	79.2)	47.8)	2.6)	2.2)	2.6)
24	68(54.2,	42(29.4,	54(40.4,	30(19.1,	2.9(2.6,	2.4(2,	2.6(2,
	79.2)	55.8)	67)	43.8)	3.2)	2.6)	3.3)
36	54(40.4,	34(22.4,	40(27.6,	22(12.8,	3.1(2.7,	2.6(2.1,	2.7(2,
30		, ,	,		, ,	, ,	
	67)	47.8)	53.8)	35.2)	3.4)	3.1)	3.4)
48	52(38.5,	28(17.5,	58(44.2,	22(12.8,	3.5(3.2,	2.7(2.1,	3(2.2,

65.2)	41.7)	70.6)	35.2)	3.8)	3.8)	3.7)

Note: n:number; ASAS: Assessment Spondyloarthritis International Society; ASAS 20: least 20 % improvement in 3 of the 4 domains- patient global assess, overall pain, function (BASFI) and inflammation (mean of BASDAI questions of morning stiffness) and no worsening; ASAS 40: least 40% improvement in the ASAS 20 domains and no worsening; ASAS 5/6: 20% improvement in ASAS 20 domains, lateral spine flexion, C-reactive protein assay; ASAS partial remission: all the 4 ASAS 20 domains score less than 2 on numeric scaling rate (NSR); ASDAS: a weighted index of disease activity-total back pain, patient global disease activity, peripheral painful/swollen joint, morning stiffness and Erythrocyte Sedimentation Rate; BASDAI: Bath disease activity index based on questions(NSR) pertaining to fatigue, neck-back-hip pains, pain/swelling in peripheral joints, discomfort on eliciting tenderness, duration and severity of early morning stiffness; BASFI: Bath functional index-10 items (NSR) pertaining to functions such as climbing steps and daily house and work related activities; See text for detail description

FIGURES:

Fig 1: Patient disposition flow chart: A study of prolonged benefit of a short term administration of biosimilar Adalimumab in active symptomatic Ankylosing Spondylitis [Adalimumab administered for initial 12 weeks in 46 patients, 4 weeks in 1 patient, 16 weeks in 3 patients, see text for details]





Figure 2: Selected Efficacy Measures (Mean) over time: An open label study of biosimilar Adalimumab in Ankylosing Spondylitis (n= 50 patients)[n:number; VAS: visual analogue scale; BASDAI and BASFI are indices of disease activity and






Figure 3: Selected Cytokine Assay (Mean) over time: An open label study of biosimilar Adalimumab in Ankylosing Spondylitis (n= 50 patients)[n:number; See text for

methods)

